Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*

Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*

BOSTON--(BUSINESS WIRE)--Minerva Biotechnology, a leading nanotechnology, cancer and stem cell development company today announced a major breakthrough in a cancer target that is widely expressed in human cancers. Minerva used its proprietary nanoparticle technology to elucidate a key molecular mechanism that is involved in cancer cell growth and metastasis. The study, published today in the journal PLoS ONE (http://www.plosone.org/doi/pone.0002054) focuses on a cell surface receptor, called MUC1, which according to extensive scientific literature is aberrantly expressed on 75% of all human solid tumors – 96% of breast cancers, 47% of prostate cancers, as well as high percentages of ovarian, colorectal, non-small cell lung, and pancreatic cancers. Circulating MUC1 is currently used as a diagnostic marker for breast cancer and over expression also has been shown by many studies to be correlated with poor clinical outcome.

Using its unique nanoparticle research platform, Minerva has shown that MUC1 is actually cleaved to a new form, called MUC1* (‘star’). Once cleaved, MUC1* dimerizes with itself and other growth factor receptors through binding of a newly discovered ligand for MUC1*, called NM23. Binding and dimerization then acts to activate the tumor to unregulated cell growth, invasion and metastasis. Blocking MUC1* dimerization and NM23 binding leads to cancer cell death. Minerva has identified both antibody-based and small molecule therapeutics that disable the receptor and block cancer cell growth.

This new discovery may also lead to better diagnostics. In collaboration with a leading diagnostic reference lab in California, Minerva has shown that MUC1* is expressed to much higher levels than MUC1 in a variety of human tumor tissues, and in the future could provide both diagnostic and prognostic information on tumor development.

About Minerva Biotechnologies

Minerva is a US-headquartered company focused on a next generation novel nanoparticle platform. Minerva enjoys a broad and dominant intellectual property position in the field of nanotechnology with over 100 patents or patent applications filed with US and worldwide rights reserved. Minerva’s intellectual property covers a wide range of uses for its nanoparticle systems in fields as diverse as drug discovery, proteomics, opto-electronics and nano-scale biosensors. Minerva has focused squarely on drug discovery and diagnostics for cancer and stem cell treatments and has used its nanotechnology in-house to expedite novel target identification and new drug development. For more information, visit www.MinervaBio.com

Copyright © 2008, Minerva Biotechnologies. All rights reserved.


Minerva Biotechnology
Cynthia Bamdad, 617-821-8773

Views: 83


You need to be a member of The International NanoScience Community to add comments!

Join The International NanoScience Community

Latest Activity

Welcome - about us

Welcome! Nanopaprika was cooked up by Hungarian chemistry PhD student in 2007. The main idea was to create something more personal than the other nano networks already on the Internet. Community is open to everyone from post-doctorial researchers and professors to students everywhere.

There is only one important assumption: you have to be interested in nano!

Nanopaprika is always looking for new partners, if you have any idea, contact me at editor@nanopaprika.eu

Dr. András Paszternák, founder of Nanopaprika

Publications by A. Paszternák:

Smartphone-Based Extension of the Curcumin/Cellophane pH Sensing Method

Pd/Ni Synergestic Activity for Hydrogen Oxidation Reaction in Alkaline Conditions

The potential use of cellophane test strips for the quick determination of food colours

pH and CO2 Sensing by Curcumin-Coloured Cellophane Test Strip

Polymeric Honeycombs Decorated by Nickel Nanoparticles

Directed Deposition of Nickel Nanoparticles Using Self-Assembled Organic Template,

Organometallic deposition of ultrasmooth nanoscale Ni film,

Zigzag-shaped nickel nanowires via organometallic template-free route

Surface analytical characterization of passive iron surface modified by alkyl-phosphonic acid layers

Atomic Force Microscopy Studies of Alkyl-Phosphonate SAMs on Mica

Amorphous iron formation due to low energy heavy ion implantation in evaporated 57Fe thin films

Surface modification of passive iron by alkylphosphonic acid layers

Formation and structure of alkylphosphonic acid layers on passive iron

Structure of the nonionic surfactant triethoxy monooctylether C8E3 adsorbed at the free water surface, as seen from surface tension measurements and Monte Carlo simulations

Next partner events of TINC

We are Media Partner of: